Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro-osteogenic paracrine response: TERCELOI clinical trial
Arantza Infante, Blanca Gener, Miguel Vázquez, Nerea Olivares, Arantza Arrieta, Gema Grau, Isabel Llano, Luis Madero, Ana Maria Bueno, Belén Sagastizabal, Daniela Gerovska, Marcos J Araúzo-Bravo, Itziar Astigarraga, Clara I Rodríguez, Arantza Infante, Blanca Gener, Miguel Vázquez, Nerea Olivares, Arantza Arrieta, Gema Grau, Isabel Llano, Luis Madero, Ana Maria Bueno, Belén Sagastizabal, Daniela Gerovska, Marcos J Araúzo-Bravo, Itziar Astigarraga, Clara I Rodríguez
Abstract
Background: Osteogenesis imperfecta (OI) is a rare genetic disease characterized by bone fragility, with a wide range in the severity of clinical manifestations. The majority of cases are due to mutations in the COL1A1 or COL1A2 genes, which encode type I collagen. Mesenchymal stem cells (MSCs), as the progenitors of the osteoblasts, the main type I collagen secreting cell type in the bone, have been proposed and tested as an innovative therapy for OI with promising but transient outcomes.
Methods: To overcome the short-term effect of MSCs therapy, we performed a phase I clinical trial based on reiterative infusions of histocompatible MSCs, administered in a 2.5-year period, in two pediatric patients affected by severe and moderate OI. The aim of this study was to assess the safety and effectiveness of this cell therapy in nonimmunosuppressed OI patients. The host response to MSCs was studied by analyzing the sera from OI patients, collected before, during, and after the cell therapy.
Results: We first demonstrated that the sequential administration of MSCs was safe and improved the bone parameters and quality of life of OI patients along the cell treatment plus 2-year follow-up period. Moreover, the study of the mechanism of action indicated that MSCs therapy elicited a pro-osteogenic paracrine response in patients, especially noticeable in the patient affected by severe OI.
Conclusions: Our results demonstrate the feasibility and potential of reiterative MSCs infusion for two pediatric OI and highlight the paracrine response shown by patients as a consequence of MSCs treatment.
Keywords: cell therapy; mesenchymal stem cell; paracrine mechanism of action; regenerative medicine.
Conflict of interest statement
The authors declare no conflict of interest.
© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
Figures
References
- Marini JC, Forlino A, Bächinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052 10.1038/nrdp.2017.52
- Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657‐1671.
- Kang H, Aryal A C S, Marini JC. Osteogenesis imperfecta: new genes reveal novel mechanisms in bone dysplasia. Transl Res. 2017;181:27‐48.
- Rauch F, Fahiminiya S, Majewski J, et al. Cole‐Carpenter syndrome is caused by a heterozygous missense mutation in P4HB. Am J Hum Genet. 2015;96(3):425‐431.
- Moosa S, Chung BH, Tung JY, et al. Mutations in SEC24D cause autosomal recessive osteogenesis imperfecta. Clin Genet. 2016;89(4):517‐519.
- Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418):1377‐1385.
- Gelse K, Pöschl E, Aigner T. Collagens–structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003;55(12):1531‐1546.
- Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat. 2007;28(3):209‐221.
- Rauch F, Lalic L, Roughley P, Glorieux FH. Genotype‐phenotype correlations in nonlethal osteogenesis imperfecta caused by mutations in the helical domain of collagen type I. Eur J Hum Genet. 2010;18(6):642‐647.
- Ben Amor IM, Glorieux FH, Rauch F. Genotype‐phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos. 2011;2011:540178.
- Lindahl K, Åström E, Rubin CJ, et al. Genetic epidemiology, prevalence, and genotype‐phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet. 2015;23(8):1112.
- Maioli M, Gnoli M, Boarini M, et al. Genotype‐phenotype correlation study in 364 osteogenesis imperfecta Italian patients. Eur J Hum Genet. 2019;27(7):1090‐1100.
- Rossi V, Lee B, Marom R. Osteogenesis imperfecta: advancements in genetics and treatment. Curr Opin Pediatr. 2019;31(6):708‐715.
- Garganta MD, Jaser SS, Lazow MA, et al. Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta. BMC Musculoskelet Disord. 2018;19(1):344.
- Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow‐derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5(3):309‐313.
- Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow‐derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99(13):8932‐8937.
- Pereira RF, Halford KW, O'Hara MD, et al. Cultured adherent cells from marrow can serve as long‐lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA. 1995;92(11):4857‐4861.
- Cabral WA, Marini JC. High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta. Am J Hum Genet. 2004;74(4):752‐760.
- Götherström C, Westgren M, Shaw SW, et al. Pre‐ and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two‐center experience. Stem Cells Transl Med. 2014;3(2):255‐264.
- Le Blanc K, Götherström C, Ringdén O, et al. Fetal mesenchymal stem‐cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005;79(11):1607‐1614.
- Otsuru S, Gordon PL, Shimono K, et al. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood. 2012;120(9):1933‐1941.
- Otsuru S, Desbourdes L, Guess AJ, et al. Extracellular vesicles released from mesenchymal stromal cells stimulate bone growth in osteogenesis imperfecta. Cytotherapy. 2018;20(1):62‐73.
- Alberich‐Bayarri A, Marti‐Bonmati L, Sanz‐Requena R, Belloch E, Moratal D. In vivo trabecular bone morphologic and mechanical relationship using high‐resolution 3‐T MRI. AJR Am J Roentgenol. 2008;191(3):721‐726.
- Alberich‐Bayarri A, Martí‐Bonmatí L, Sanz‐Requena R, et al. Reproducibility and accuracy in the morphometric and mechanical quantification of trabecular bone from 3 Tesla magnetic resonance images. Radiologia. 2014;56(1):27‐34.
- Alberich‐Bayarri A, Marti‐Bonmati L, Angeles Pérez M, et al. Assessment of 2D and 3D fractal dimension measurements of trabecular bone from high‐spatial resolution magnetic resonance images at 3 T. Med Phys. 2010;37(9):4930‐4937.
- Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800‐812.
- McGrath PJ, Walco GA, Turk DC, et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J Pain. 2008;9(9):771‐783.
- Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript‐level expression analysis of RNA‐seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 2016;11(9):1650‐1667.
- Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA‐seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562‐578.
- Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work with high‐throughput sequencing data. Bioinformatics. 2015;31(2):166‐169.
- Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078‐2079.
- Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841‐842.
- del Rio L, Carrascosa A, Pons F, Gusinyé M, Yeste D, Domenech FM. Bone mineral density of the lumbar spine in white Mediterranean Spanish children and adolescents: changes related to age, sex, and puberty. Pediatr Res. 1994;35(3):362‐366.
- Zack P, Franck L, Devile C, Clark C. Fracture and non‐fracture pain in children with osteogenesis imperfecta. Acta Paediatr. 2005;94(9):1238‐1242.
- O'Keefe RJ, Tuan RS, Lane NE, et al. American Society for Bone and Mineral Research‐Orthopaedic Research Society Joint Task Force Report on Cell‐Based Therapies. J Bone Miner Res. 2020;35(1):3‐17.
- Tsimicalis A, Boitor M, Ferland CE, et al. Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle. Eur J Pediatr. 2018;177(6):891‐902.
- Vanz AP, van de Sande Lee J, Pinheiro B, et al. Health‐related quality of life of children and adolescents with osteogenesis imperfecta: a cross‐sectional study using PedsQL™. BMC Pediatr. 2018;18(1):95.
- Horowitz AM, Fan X, Bieri G, et al. Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain. Science. 2020;369(6500):167‐173.
- Gregory P, Kraemer E, Zürcher G, et al. GPI‐specific phospholipase D (GPI‐PLD) is expressed during mouse development and is localized to the extracellular matrix of the developing mouse skeleton. Bone. 2005;37(2):139‐147.
- Soifer HS, Rossi JJ, Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther. 2007;15(12):2070‐2079.
- Kocijan R, Muschitz C, Geiger E, et al. Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures. J Clin Endocrinol Metab. 2016;101(11):4125‐4134.
- Ladang A, Beaudart C, Locquet M, Reginster JY, Bruyère O, Cavalier E. Evaluation of a panel of microRNAs that predicts fragility fracture risk: a pilot study. Calcif Tissue Int. 2020;106(3):239‐247.
- Li CJ, Cheng P, Liang MK, et al. MicroRNA‐188 regulates age‐related switch between osteoblast and adipocyte differentiation. J Clin Invest. 2015;125(4):1509‐1522.
- Li D, Liu J, Guo B, et al. Osteoclast‐derived exosomal miR‐214‐3p inhibits osteoblastic bone formation. Nat Commun. 2016;7:10872.
- Zarecki P, Hackl M, Grillari J, Debono M, Eastell R. Serum microRNAs as novel biomarkers for osteoporotic vertebral fractures. Bone. 2020;130:115105.
- Infante A, Rodríguez CI. Osteogenesis and aging: lessons from mesenchymal stem cells. Stem Cell Res Ther. 2018;9(1):244.
- Shoucri BM, Martinez ES, Abreo TJ, et al. Retinoid X receptor activation alters the chromatin landscape to commit mesenchymal stem cells to the adipose lineage. Endocrinology. 2017;158(10):3109‐3125.
- von Schroeder HP, Veillette CJ, Payandeh J, Qureshi A, Heersche JN. Endothelin‐1 promotes osteoprogenitor proliferation and differentiation in fetal rat calvarial cell cultures. Bone. 2003;33(4):673‐684.
- Clines GA, Mohammad KS, Bao Y, et al. Dickkopf homolog 1 mediates endothelin‐1‐stimulated new bone formation. Mol Endocrinol. 2007;21(2):486‐498.
- Clines GA, Mohammad KS, Grunda JM, et al. Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. J Bone Miner Res. 2011;26(10):2523‐2536.
- Guntur AR, Gerencser AA, Le PT, et al. Osteoblast‐like MC3T3‐E1 cells prefer glycolysis for ATP production but adipocyte‐like 3T3‐L1 cells prefer oxidative phosphorylation. J Bone Miner Res. 2018;33(6):1052‐1065.
- Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem. 2009;284(10):6038‐6042.
- van de Peppel J, Strini T, Tilburg J, Westerhoff H, van Wijnen AJ, van Leeuwen JP. Identification of three early phases of cell‐fate determination during osteogenic and adipogenic differentiation by transcription factor dynamics. Stem Cell Rep. 2017;8(4):947‐960.
- Flowers S, Nagl NG, Beck GR, Moran E. Antagonistic roles for BRM and BRG1 SWI/SNF complexes in differentiation. J Biol Chem. 2009;284(15):10067‐10075.
- Liu S, Liu D, Chen C, et al. MSC transplantation improves osteopenia via epigenetic regulation of notch signaling in lupus. Cell Metab. 2015;22(4):606‐618.
- Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone‐marrow‐derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012;18(5):759‐765.
- Martin I, Galipeau J, Kessler C, Le Blanc K, Dazzi F. Challenges for mesenchymal stromal cell therapies. Sci Transl Med. 2019;11(480):eaat2189.
- Wang Z, Lu Y, Zhang X, et al. Serum microRNA is a promising biomarker for osteogenesis imperfecta. Intractable Rare Dis Res. 2012;1(2):81‐85.
- Munir S, Basu A, Maity P, et al. TLR4‐dependent shaping of the wound site by MSCs accelerates wound healing. EMBO Rep. 2020;21(5):e48777.
- Jones GN, Moschidou D, Lay K, et al. Upregulating CXCR4 in human fetal mesenchymal stem cells enhances engraftment and bone mechanics in a mouse model of osteogenesis imperfecta. Stem Cells Transl Med. 2012;1(1):70‐78.
- Boberg E, von Bahr L, Afram G, et al. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: a phase II study. Stem Cells Transl Med. 2020;9(10):1190‐1202.
- Martin‐Rufino JD, Lozano FS, Redondo AM, et al. Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger's disease). Stem Cell Res Ther. 2018;9(1):150.
- Riordan NH, Hincapié ML, Morales I, et al. Allogeneic human umbilical cord mesenchymal stem cells for the treatment of autism spectrum disorder in children: safety profile and effect on cytokine levels. Stem Cells Transl Med. 2019;8(10):1008‐1016.
- Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207‐210.
Source: PubMed